Genentech, an independent subsidiary of Roche, is expanding the initial investment in its new biomanufacturing facility in Holly Springs, N.C., from $700 million to approximately $2 billion. Originally envisioned as a 700,000-sf complex, the project will now deliver increased production volume and scale capacity, significantly enhancing the company's U.S. supply chain. Key drivers in this strategic decision included access to the region's strong academic institutions and qualified professionals, as well as proximity to other leading life science companies in the Raleigh-Durham area.
Construction began in August of 2025 on the state-of-the-art hub, which will produce next-generation treatments for metabolic conditions such as obesity. Set to be operational by 2029, the center will leverage advanced automation solutions and digital technologies to maximize efficiency and sustainability. The development supports Roche and Genentech’s broader $50 billion commitment to U.S. manufacturing, and reflects Genentech's shared goal with the U.S. administration to strengthen domestic production and innovation.
